RecruitingPhase 2NCT06800651

Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sponsor

Jemincare

Enrollment

135 participants

Start Date

Mar 13, 2025

Study Type

INTERVENTIONAL

Conditions

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Summary

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JMKX003142 will be administered orally and a drug called Plcacebo for people with adpkd (autosomal dominant polycystic kidney disease). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJMKX003142 will be administered orally

JMKX003142 will be administered orally

DRUGPlcacebo

matched to JMKX003142

Locations(1)

Peking University First Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06800651

Related Trials

The German ADPKD Tolvaptan Treatment Registry

NCT0249752112 locations

Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

NCT066186389 locations